The MAA for VIZZ (aceclidine ophthalmic solution) 1.44% for the treatment of presbyopia in adults has been submitted to the MHRA – LENZ Therapeutics

LENZ Therapeutics announced that it has submitted a Marketing Authorization Application (MAA) to the United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA) for the review and approval of Vizz (aceclidine ophthalmic solution) 1.44%, the first and only aceclidine-based eye drop for the treatment of presbyopia in adults. Since receiving U.S. Food and Drug Administration (FDA) approval in July 2025, LENZ has moved rapidly to expand global access to Vizz , with submission of the MAA in the United Kingdom representing the sixth ex-U.S. regulatory submission for Vizz .

The MAA submission is supported by positive data from three randomized, double-masked, controlled Phase 3 studies (CLARITY trials) conducted in the United States, in which Vizz  achieved all primary and secondary endpoints, demonstrating the ability to improve near vision within 30 minutes and last up to 10 hours. Vizz  was well tolerated with no serious treatment-related adverse events observed in over 30,000 treatment days across all three CLARITY trials.